February 23rd 2016
An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.
February 22nd 2016
Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.
February 19th 2016
In patients treated with definitive radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma, most recurrences can be detected via imaging at 3 months and physical examinations during the first 6 months after treatment.